FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s
3 marzo 2026
Leggi
Impact of early and tight HbA1c control on the risk of long-term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register
Mount J, Boye K, Lebrec J, Wilkes E, et al.
Diabetes Obes Metab. Pub. online 27 Feb 2026.
Leggi
Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: a real-world observational study
Ipaye T, Goldney J, Yates T, et al.
Diabetes Obes Metab. Pub. online 26 Feb 2026.
Leggi
Effects of sodium/glucose cotransporter-2 inhibitor use on mortality, amputation, and healing in patients with diabetic foot ulcer
Dumortier C, Aho Glele S, Rouland A, et al.
Diabetes Care. Pub. online 25 Feb 2026.
Leggi
Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial
Wilmot EG, Beltrand J, Guerci B, et al.
Lancet Diabetes Endocrinol. Pub. online 23 Feb 2026.
Leggi
Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis
Shokravi A, Seth J, Mancini GBJ
Cardiovasc Diabetol. Pub. online 27 Feb 2026.
Leggi
AIFA: POSITION PAPER Medicina di precisione e appropriatezza della prescrizione farmacologica
23 febbraio 2026
Leggi
Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: a network meta-analysis of randomised trials
Chiappa GR, Santos PCN, Calvacante DVS, et al.
Diabetes Obes Metab. Pub. online 23 Feb 2026.
Leggi
Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetes
Leohr J, Klein O, Heise T, et al.
Diabetes Obes. Metab. Pub. online 23 Feb 2026.
Leggi
Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2 4 mg, an Italian real-world study
Pampanelli S, Terzoni S, Pantanetti P, et al.
Diabetes Obes Metab. Pub. online 23 Feb 2026.
Leggi